Safety, Tolerability, and Preliminary Efficacy of the Anti-Fibrotic Small Molecule PRI-724, a CBP/β-Catenin Inhibitor, in Patients with Hepatitis C Virus-related Cirrhosis: A Single-Center, Open-Label, Dose Escalation Phase 1 Trial - Concepedia

Concepedia

Publication | Open Access

Safety, Tolerability, and Preliminary Efficacy of the Anti-Fibrotic Small Molecule PRI-724, a CBP/β-Catenin Inhibitor, in Patients with Hepatitis C Virus-related Cirrhosis: A Single-Center, Open-Label, Dose Escalation Phase 1 Trial

DOI Full Paper Access

100

Citations

20

References

2017

Year

Kiminori Kimura, Akemi Ikoma, Maki Shibakawa, Shinji Shimoda, Kenichi Harada, Masanao Saio, Jun Imamura, Yosuke Osawa, Masamichi Kimura, Koji Nishikawa,

References

	Year	Citations

Page 1